Provided By GlobeNewswire
Last update: Nov 11, 2025
WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentations at the following investor conferences:
Read more at globenewswire.comNASDAQ:ZBIO (12/3/2025, 1:41:09 PM)
36.13
+1.63 (+4.72%)
Find more stocks in the Stock Screener


